The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 11, 2012
Filed:
Sep. 27, 2010
Nicole Blaquiere, South San Francisco, CA (US);
Steven DO, South San Francisco, CA (US);
Danette Dudley, South San Francisco, CA (US);
Adrian Folkes, Basel, CH;
Richard Goldsmith, South San Francisco, CA (US);
Robert Heald, Harlow, GB;
Timothy Heffron, South San Francisco, CA (US);
Aleksandr Kolesnikov, South San Francisco, CA (US);
Chudi Ndubaku, South San Francisco, CA (US);
Alan G. Olivero, South San Francisco, CA (US);
Stephen Price, Harlow, GB;
Steven Staben, South San Francisco, CA (US);
Binqing Wei, South San Francisco, CA (US);
Nicole Blaquiere, South San Francisco, CA (US);
Steven Do, South San Francisco, CA (US);
Danette Dudley, South San Francisco, CA (US);
Adrian Folkes, Basel, CH;
Richard Goldsmith, South San Francisco, CA (US);
Robert Heald, Harlow, GB;
Timothy Heffron, South San Francisco, CA (US);
Aleksandr Kolesnikov, South San Francisco, CA (US);
Chudi Ndubaku, South San Francisco, CA (US);
Alan G. Olivero, South San Francisco, CA (US);
Stephen Price, Harlow, GB;
Steven Staben, South San Francisco, CA (US);
BinQing Wei, South San Francisco, CA (US);
F. Hoffman-La Roche AG, , CH;
Abstract
Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and where (i) Xis N and Xis S, (ii) Xis S and Xis N, (iii) Xis CRand Xis S, (iv) Xis S and Xis CR; (v) Xis NRand Xis N, (vi) Xis N and Xis NR, (vii) Xis CRand Xis O, (viii) Xis O and Xis CR, (ix) Xis CRand Xis C(R), (x) Xis C(R)and Xis CR; (xi) Xis N and Xis O, or (xii) Xis O and Xis N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.